Quality key factors
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-26.44%
EBIT to Interest (avg)
-84.45
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.87
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.27%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.97
EV to EBIT
-6.67
EV to EBITDA
-6.67
EV to Capital Employed
23.63
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-354.50%
ROE (Latest)
-39.74%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Movement
1What is working for the Company
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
-17What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -126.62 MM
ROCE(HY)
Lowest at -50.13%
PRE-TAX PROFIT(Q)
At USD -31.4 MM has Fallen at -43.54%
NET PROFIT(Q)
At USD -31.4 MM has Fallen at -43.54%
Here's what is working for Arrivent BioPharma, Inc.
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Arrivent BioPharma, Inc.
Operating Cash Flow
Lowest at USD -126.62 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD -31.4 MM has Fallen at -43.54%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -31.4 MM has Fallen at -43.54%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)






